Waregem (Belgium) / Rotterdam (Netherlands)[1], 16 March 2012 (7.30 a.m.) – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV is announcing today that the number of shares held by Arseus NV has fallen below the disclosure threshold of 3%.
The number of own shares held by Arseus NV has decreased from 1,097,585 shares to 760,345 shares. This decrease is the result of the transfer of € 4 million in own shares as payment for the acquisition of the Brazilian Pharma Nostra in 2011. On 13 March 2012, Arseus transferred 337,240 shares at a price of € 11.8610 per share.
Based on the total of 31,216,888 (total number of voting rights) and the relevant notifications received by Arseus, today the shareholder structure of Arseus is as follows:
Number of shares % of the total EnHold NV 8,166,908 26.16% Alychlo NV/Coucke 3,528,080 11.30% BNP Paribas Investment Partners SA 1,546,052 4.95% Arseus NV 760,345 2.44% Public 17,215,503 55.15%The original notification forms are available at www.arseus.com. Detailed information about the acquisition of the Brazilian Pharma Nostra is available in the press release of 11 July 2011. This press release can be viewed at www.arseus.com.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the full press release: